A 45-Year-Old With a Thyroid Gland Mass

Poll

A 45-year-old man presents with neck pain and a mass in the thyroid gland. What is your diagnosis?

A 45-year-old man presents with neck pain of several weeks duration. Physical and imaging evaluation reveals a mass in the thyroid gland.

Based on the image shown, what is your diagnosis?

A. Medullary carcinoma of the thyroid
B. Papillary carcinoma of the thyroid
C. Adamantinoma-like Ewing sarcoma of the thyroid
D. Follicular carcinoma of the thyroid
Recent Videos
Findings may help providers and patients with head and neck cancer consider whether to proceed with radiotherapy modalities, such as proton therapy or IMRT.
Study results appear to affirm anecdotal information from patients with head and neck cancer related to taste changes during and after radiotherapy.
Noah S. Kalman, MD, MBA, describes the rationale for using a test to measure granular details of taste change in patients undergoing radiotherapy for HNC.
The use of a single-port robot may allow for surgically treating more patients with head and neck cancer in a more timely manner, according to Hilary McCrary, MD, MPH.
Treatment with toripalimab does not yield the same vascular toxicity seen with pembrolizumab in patients with advanced or metastatic nasopharyngeal carcinoma, according to Barbara Burtness, MD.
Overall survival also appears to improve with toripalimab compared with chemotherapy among patients with metastatic or advanced nasopharyngeal carcinoma.
Related Content
Atezolizumab/Matched-Targeted Therapy Improves OS in Anaplastic Thyroid Cancer

Atezolizumab/Matched-Targeted Therapy Improves OS in Anaplastic Thyroid Cancer

Tim Cortese
November 1st 2024
Article

Patients with anaplastic thyroid cancer had a significant boost to overall survival with atezolizumab and targeted therapy.

OncView™ Podcast: Advances in Systemic Therapy of Differentiated Thyroid Cancer

OncView™ Podcast: Advances in Systemic Therapy of Differentiated Thyroid Cancer

Lori Wirth, MD
May 12th 2022
Podcast

In an OncView™ program, Lori Wirth, MD, shared her insights into the current treatment of patients with differentiated thyroid cancer.

Data also show an improvement in major pathological response in the perioperative pembrolizumab arm of the KEYNOTE-689 trial.

Perioperative Pembrolizumab Combo Improves EFS in Locally Advanced HNSCC

Russ Conroy
October 8th 2024
Article

Data also show an improvement in major pathological response in the perioperative pembrolizumab arm of the KEYNOTE-689 trial.

Younger Thyroid Cancer Survivors at Higher Risk for Late Effects

Younger Thyroid Cancer Survivors at Higher Risk for Late Effects

Brenna Blackburn
February 17th 2017
Podcast

In this interview we discuss a study that found that survivors of thyroid cancer diagnosed with the disease at a young age had an increased risk of late effects from therapy.

“We are now able to increase the lifespan in some of these most deadly forms of thyroid cancer solely due to gene profiling and targeted medicine,” said Geoffrey David Young, MD, PhD, FACS

Taking a Multidisciplinary Approach to Thyroid Cancer Treatment

Harrison Widelitz
September 27th 2024
Article

“We are now able to increase the lifespan in some of these most deadly forms of thyroid cancer solely due to gene profiling and targeted medicine,” said Geoffrey David Young, MD, PhD, FACS.

Patients with radioiodine-refractory differentiated thyroid cancer appear to derive benefit from lenvatinib in community and academic settings.

Lenvatinib Improves Efficacy in Real-World Thyroid Cancer Settings

Morgan Bayer
September 14th 2024
Article

Patients with radioiodine-refractory differentiated thyroid cancer appear to derive benefit from lenvatinib in community and academic settings.